<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399124</url>
  </required_header>
  <id_info>
    <org_study_id>ICMRC-01</org_study_id>
    <nct_id>NCT02399124</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma</brief_title>
  <acronym>ICE-SECRET</acronym>
  <official_title>ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IceCure Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IceCure Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This experiment is designed for post marketing data collection of a cryosurgical system&#xD;
      [PROSENSE™ of IceCure Medical], for the treatment of renal cell carcinoma (RCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A post marketing data collection of a cryosurgical system [PROSENSE™] of IceCure Medical],&#xD;
      for the treatment of renal cell carcinoma (RCC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success in creating an ice ball that engulfs the whole tumor with 5 mm margins using the ProSense™ as seen under laparoscopic, US or CT imaging during the procedure.</measure>
    <time_frame>During intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success in verification of the ProSense™ safety as demonstrated by having no complications related to the cryoablation procedure other than the well-known ones.</measure>
    <time_frame>a follow up visit at 1 month, 4 months, 8 months, 12 months and every 6 months afterwards up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>single arm, open label, treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single arm, open label, treatment; ProSenseTM Cryoablation treatment, post marketing surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROSENSE™</intervention_name>
    <description>single arm, open label, PROSENSE™ treatment</description>
    <arm_group_label>single arm, open label, treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is above 18 years old.&#xD;
&#xD;
          2. The patient has enhanced solid mass of renal origin located in the kidney or elsewhere&#xD;
             proved by imaging.&#xD;
&#xD;
          3. Patient's mass size is up to 5 cm at its largest dimension.&#xD;
&#xD;
          4. Patient is able to visit the clinic as needed during the 60-month follow-up period&#xD;
             following the cryoablation procedure.&#xD;
&#xD;
          5. The patient has been informed of the study and agrees to its provisions, and has&#xD;
             signed an IRB approved written informed consent, including data privacy authorization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with permanent coagulation disorders or severe medical instability or active&#xD;
             infection.&#xD;
&#xD;
          2. Patients with any terminal illness.&#xD;
&#xD;
          3. Patient participating in other trials using drugs or devices.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Halachmi Sarel, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bnei Zion Medical Center, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bnei Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asaf Harofe Medical center</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RCC</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Kidney tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

